The estimated Net Worth of Kalevi Kurkijarvi is at least 1.38 百万$ dollars as of 17 February 2021. Kalevi Kurkijarvi owns over 6,000 units of FibroGen Inc stock worth over 15,640$ and over the last 10 years he sold FGEN stock worth over 947,080$. In addition, he makes 417,378$ as Independent Director at FibroGen Inc.
Kalevi has made over 42 trades of the FibroGen Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 6,000 units of FGEN stock worth 171,900$ on 17 February 2021.
The largest trade he's ever made was exercising 12,000 units of FibroGen Inc stock on 12 December 2017 worth over 34,800$. On average, Kalevi trades about 3,755 units every 30 days since 2014. As of 17 February 2021 he still owns at least 39,100 units of FibroGen Inc stock.
You can see the complete history of Kalevi Kurkijarvi stock trades at the bottom of the page.
Dr. Kalevi Kurkijarvi Ph.D. serves as Independent Director of the Company. He has also served on the board of directors of our subsidiary, FibroGen Europe Oy, since November 1997, and as Managing Director (Chief Executive Officer) since January 2019. Dr. Kurkijärvi has been the Chairman and Founding Partner of Innomedica Oy, a business development company specialized in licensing, distributor search, and strategic planning for companies in the pharmaceutical, diagnostics, and biotechnology industries, since March 2010, and from August 1997 to February 2010 he acted as Director having financial matters as his main responsibility. He was also the Founding Partner and former Chairman and Chief Executive Officer of Bio Fund Management Ltd, a Finnish-Danish venture capital company, from 1997 until 2010. He has also been Chairman and Chief Executive Officer of his family’s import-export trading company, Biketex Ltd, since October 1993. Dr. Kurkijärvi has more than twenty years’ experience in international life science business and over ten years in corporate finance. He currently serves on the boards of directors of Innomedica Oy (Chair), Biketex Ltd (Chair) and Idea Development ID Oy (Chair). He previously served on the boards of directors at other biotechnology companies such as of Paratek Pharmaceuticals Inc., Ark Therapeutics Plc, BioTie Therapies Plc (Chair), Hytest Oy (Chair), Stick Tech Oy (Chair), Hormos Medical Oy (Chair), Map Medical Oy (Chair), Bio Orbit Oy (Chair) and Juvantia Pharma Oy, among others. Prior to founding Bio Fund, Dr. Kurkijärvi worked as Executive Director of the venture capital group at the Finnish National Fund of Research and Development (SITRA). He has also served as Executive Vice President at Wallac Oy, and as President and Chief Executive Officer of Pharmacia Diagnostics Production Oy. Dr. Kurkijärvi received a Doctor of Philosophy degree in Biochemistry and Molecular Biology from the University of Turku in 1992, where he also worked for several years in research and teaching.
As the Independent Director of FibroGen Inc, the total compensation of Kalevi Kurkijarvi at FibroGen Inc is 417,378$. There are 17 executives at FibroGen Inc getting paid more, with Kin-Hung Yu having the highest compensation of 5,856,450$.
Kalevi Kurkijarvi is 68, he's been the Independent Director of FibroGen Inc since 1996. There are 2 older and 20 younger executives at FibroGen Inc. The oldest executive at FibroGen Inc is Thomas Kearns, 83, who is the Lead Independent Director.
Kalevi's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.
Over the last 10 years, insiders at FibroGen Inc have traded over 188,593,537$ worth of FibroGen Inc stock and bought 106,523 units worth 1,309,423$ . The most active insiders traders include Rory B Riggs、Thomas B Neff、Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of 6,963$. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth 25,884$.
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
FibroGen Inc executives and other stock owners filed with the SEC include: